Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
TransMedics: Funds totaling $29.75 mil. raised in a recent Series C financing led by 3i Group will be used to support expanded clinical trials for TransMedics' Organ Care System. The organ transport system is designed to optimize organ health and increase the number of usable transplant organs by maintaining the tissue in a warm, functioning state outside of the body. The firm anticipates European approval for the system for heart transplants in early 2007 following the completion of its PROTECT trial in the UK. Thanks to the funds raised, TransMedics plans to initiate trials in the U.S. and Europe and to extend its platform for use with additional organs such as the lungs, liver and kidneys...